Inogen, Inc. (NASDAQ:INGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00

Shareholders in Inogen, Inc. (NASDAQ:INGN) had a terrible week, as shares crashed 23% to US$7.95 in the week since its latest yearly results. Revenues of US$336m were in line with expectations, although statutory losses per share were US$1.52, some 11% smaller than was expected. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

Check out our latest analysis for Inogen

Following the latest results, Inogen's four analysts are now forecasting revenues of US$350.7m in 2025. This would be a credible 4.5% improvement in revenue compared to the last 12 months. The loss per share is expected to ameliorate slightly, reducing to US$1.45. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$343.6m and losses of US$1.50 per share in 2025. It looks like there's been a modest increase in sentiment in the recent updates, with the analysts becoming a bit more optimistic in their predictions for both revenues and losses per share.

The consensus price target rose 5.3% to US$10.00, with the analysts encouraged by the higher revenue and lower forecast losses for next year.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. For example, we noticed that Inogen's rate of growth is expected to accelerate meaningfully, with revenues forecast to exhibit 4.5% growth to the end of 2025 on an annualised basis. That is well above its historical decline of 0.3% a year over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenue grow 7.8% per year. So although Inogen's revenue growth is expected to improve, it is still expected to grow slower than the industry.

The Bottom Line

The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. They also upgraded their revenue estimates for next year, even though it is expected to grow slower than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for Inogen going out to 2027, and you can see them free on our platform here.

However, before you get too enthused, we've discovered 1 warning sign for Inogen that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.